Daman partners with Gilead Sciences, Galapagos to advance RA app

Daman announced on Tuesday a partnership agreement with Gilead Sciences and Galapagos to advance its RheumaBuddy application in 15 markets globally, aiming to reach more people with rheumatoid arthritis (RA). Daman CEO Andreas Dam remarked that "there is a huge unmet need among RA patients to give more holistic care offerings. The partnership enables us to take important steps in the direction."

According to Daman, the RheumaBuddy app, which it said is used by more than 13, 000 RA patients in Europe since its launch in 2014, is a next-generation context-aware algorithm-driven app designed to help patients self-manage their disease. Built on the HealthBuddy platform, which is applied within several disease areas globally, RheumaBuddy is transforming into a platform, benefiting all stakeholders in rheumatology care, including patients, healthcare professionals, and pharmaceutical companies, Daman said.

The partnership agreement with Gilead Sciences and Galapagos runs until September 15, 2021 with the possibility of extension. Daman noted that the agreement provides a sponsorship only, while the platform's functionalities and content are still co-created by patients, healthcare professionals and Daman.

To ensure you don't miss other Top Stories like these and news on key medtech industry developments, sign up for our free daily e-newsletter here.  

Did you like this article?